上海医药
上海醫藥
상해의약
SHANGHAI MEDICAL & PHARMACEUTICAL JOURNAL
2015年
9期
42-44,70
,共4页
宫颈癌%磁共振扩散加权成像%表观扩散系数%疗效%预测
宮頸癌%磁共振擴散加權成像%錶觀擴散繫數%療效%預測
궁경암%자공진확산가권성상%표관확산계수%료효%예측
cervical cancer%DWI%ADC%curative effect%prediction
目的：探讨磁共振扩散加权成像（DWI）在宫颈癌诊断和新辅助化疗（NACT）疗效预测中的应用价值。方法：选取2012年8月-2014年2月在我院就诊的宫颈癌患者64例和21例无明显宫颈病变的健康志愿者行常规MRI和DWI检查，比较病变宫颈癌和正常宫颈及不同分期宫颈组织的ADC值，并分析化疗前后宫颈癌组织的ADC值变化。结果：宫颈癌ADC值明显低于正常宫颈（P＜0.05）；ADC值诊断宫颈癌的ROC曲线下面积（AUC）为0.847，95%可信区间为0.731～0.972；不同分期宫颈癌ADC值比较，差异具有统计学意义（P＜0.05）；宫颈癌治疗后有效患者16例，无效患者6例，有效患者中，第2次化疗后的ADC值明显较第1次化疗和治疗前高（P＜0.05），第1次化疗后ADC值与治疗前比较，差异无显著性（P＞0.05），无效患者在治疗前、第1次及第2次化疗的ADC值间的差异无显著性（P＞0.05）。结论：DWI可鉴别宫颈癌和正常宫颈，有助于宫颈癌的诊断和疗效的预测。
目的：探討磁共振擴散加權成像（DWI）在宮頸癌診斷和新輔助化療（NACT）療效預測中的應用價值。方法：選取2012年8月-2014年2月在我院就診的宮頸癌患者64例和21例無明顯宮頸病變的健康誌願者行常規MRI和DWI檢查，比較病變宮頸癌和正常宮頸及不同分期宮頸組織的ADC值，併分析化療前後宮頸癌組織的ADC值變化。結果：宮頸癌ADC值明顯低于正常宮頸（P＜0.05）；ADC值診斷宮頸癌的ROC麯線下麵積（AUC）為0.847，95%可信區間為0.731～0.972；不同分期宮頸癌ADC值比較，差異具有統計學意義（P＜0.05）；宮頸癌治療後有效患者16例，無效患者6例，有效患者中，第2次化療後的ADC值明顯較第1次化療和治療前高（P＜0.05），第1次化療後ADC值與治療前比較，差異無顯著性（P＞0.05），無效患者在治療前、第1次及第2次化療的ADC值間的差異無顯著性（P＞0.05）。結論：DWI可鑒彆宮頸癌和正常宮頸，有助于宮頸癌的診斷和療效的預測。
목적：탐토자공진확산가권성상（DWI）재궁경암진단화신보조화료（NACT）료효예측중적응용개치。방법：선취2012년8월-2014년2월재아원취진적궁경암환자64례화21례무명현궁경병변적건강지원자행상규MRI화DWI검사，비교병변궁경암화정상궁경급불동분기궁경조직적ADC치，병분석화료전후궁경암조직적ADC치변화。결과：궁경암ADC치명현저우정상궁경（P＜0.05）；ADC치진단궁경암적ROC곡선하면적（AUC）위0.847，95%가신구간위0.731～0.972；불동분기궁경암ADC치비교，차이구유통계학의의（P＜0.05）；궁경암치료후유효환자16례，무효환자6례，유효환자중，제2차화료후적ADC치명현교제1차화료화치료전고（P＜0.05），제1차화료후ADC치여치료전비교，차이무현저성（P＞0.05），무효환자재치료전、제1차급제2차화료적ADC치간적차이무현저성（P＞0.05）。결론：DWI가감별궁경암화정상궁경，유조우궁경암적진단화료효적예측。
Objective: To estimate the value of diffusion weighted magnetic resonance imaging (DWI) in the diagnosis of cervical cancer and the monitoring of neoadjuvant chemotherapy (NACT) efifcacy.Methods:MRI and DWI were performed in 64 cases of patients with cervical cancer and 21 cases of healthy volunteers, and the ADC value of uterine cervix lesions and normal cervix and the different stages of cervical cancer were compared, and the ADC value of patients with different effect in different time points after treatment were compared.Results: The ADC was signiifcantly lower in the patients with cervical cancer than in the volunteers. The area of ROC was 0.847, and 95% conifdence interval was 0.731~0.972. There was a signiifcant difference between the ADC of different stages of cervical cancer. In all patients with cervical cancer, 16 cases of patients were effective (CR+PR), and 6 cases nvalid (PD+SD), the ADC after the second chemotherapy was signiifcantly higher than that after the ifrst chemotherapy and before treatment in the effective group, and there were no signiifcant differences in ADCs after the ifrst chemotherapy and before treatment and no signiifcant difference neither in ADCs after the ifrst and second chemotherapy and before treatment.Conclusion:DWI can be used to distinguish cervical carcinoma from normal cervical, and can be helpful to the diagnosis of cervical cancer and the monitoring of NACT efifcacy.
